Beacon Pharmaceuticals PLC Stock price

Equities

BEACONPHAR

BD0482BECON5

Pharmaceuticals

End-of-day quote Dhaka S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
198.3 BDT -1.20% Intraday chart for Beacon Pharmaceuticals PLC -9.53% -19.06%
Sales 2022 8.02B 72.97M Sales 2023 8.51B 77.4M Capitalization 56.6B 515M
Net income 2022 935M 8.5M Net income 2023 510M 4.64M EV / Sales 2022 7.85 x
Net Debt 2022 3.28B 29.85M Net Debt 2023 6.98B 63.46M EV / Sales 2023 7.47 x
P/E ratio 2022
63.8 x
P/E ratio 2023
111 x
Employees 3,872
Yield 2022
0.62%
Yield 2023
0.65%
Free-Float 36.94%
More Fundamentals * Assessed data
Dynamic Chart
Beacon Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company Secretary CI
Beacon Pharmaceuticals PLC Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Beacon Pharmaceuticals PLC Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023 CI
Beacon Pharmaceuticals plc Appoints Mr. Ulfat Karim as the Director and Chief Operating Officer CI
Beacon Pharmaceuticals PLC Announces Appointment of Jalal Uddin as Chief Financial Officer CI
Beacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as CFO CI
Beacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as Director (Finance & Accounts) CI
Beacon Pharmaceuticals PLC Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Beacon Pharmaceuticals Limited will Change its Name to Beacon Pharmaceuticals PLC CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended June 30, 2022 CI
Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022 CI
More news
1 day-1.20%
1 week-9.53%
Current month-16.12%
1 month-16.43%
3 months-19.06%
6 months-19.06%
Current year-19.06%
More quotes
1 week
195.10
Extreme 195.1
224.00
1 month
195.10
Extreme 195.1
252.50
Current year
195.10
Extreme 195.1
288.90
1 year
195.10
Extreme 195.1
288.90
3 years
97.20
Extreme 97.2
393.00
5 years
18.00
Extreme 18
393.00
10 years
11.20
Extreme 11.2
393.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 01-09-11
Director of Finance/CFO - -
Chief Administrative Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 67 01-09-11
Chairman 64 -
Director/Board Member 39 -
More insiders
Date Price Change Volume
24-03-28 198.3 -1.20% 112,256
24-03-27 200.7 -1.81% 178,288
24-03-25 204.4 -3.36% 111,416
24-03-24 211.5 -3.51% 153,819
24-03-21 219.2 +2.72% 124,827

End-of-day quote Dhaka S.E., March 27, 2024

More quotes
Beacon Pharmaceuticals PLC, formerly Beacon Pharmaceuticals Limited, is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract manufacturing and tool manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral and biotech. Its products include Favipiravir, Remdisivir INN, Meropenem, Bendamustine, Bleomycin Sulfate, Daunorubicin, Gemcitabine, Darbepoetin alfa and Filgrastim.
More about the company
  1. Stock
  2. Equities
  3. Stock Beacon Pharmaceuticals PLC - Dhaka S.E.